Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 3/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679771 | 0.81 | POLB (0.41) | POLBSMN1; SMN2KDM4EGAA | |
| SCHEMBL24666062 | 0.81 | POLB (0.36) | POLBPDPK1METAP1SMN1; SMN2SSTR4 | |
| SCHEMBL30759203 | 0.81 | POLB (0.36) | POLBPDPK1METAP1SMN1; SMN2SSTR4 | |
| SCHEMBL20631816 | 0.78 | SSTR4 (0.41) | POLBPDPK1METAP1SSTR4TACR1 | |
| SCHEMBL29145511 | 0.75 | TRPV1 (0.40) | POLBPDPK1SMN1; SMN2SSTR4KDM4E | |
| SCHEMBL29450030 | 0.75 | TRPV1 (0.40) | POLBPDPK1SMN1; SMN2SSTR4KDM4E | |
| SCHEMBL26135106 | 0.75 | TRPM8 (0.41) | POLBSMN1; SMN2KDM4EGAA | |
| SCHEMBL17111477 | 0.75 | TACR1 (0.38) | SMN1; SMN2TACR1KDM4E | |
| SCHEMBL1322072 | 0.75 | PLCG1 (0.35) | POLBUSP30PDPK1METAP1SSTR4 | |
| SCHEMBL27152922 | 0.75 | POLB (0.34) | POLBMETAP1SSTR4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | TRPV4 410/4885POLB 2931/4885USP30 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.